Skip to content
Menu

Citizens Maintains Market Outperform on Zymeworks, Raises Price Target to $39

Benzinga Newsdesk 1 week ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Citizens analyst Reni Benjamin maintains Zymeworks (NASDAQ:ZYME) with a Market Outperform and raises the price target from $32 to $39.

Citizens analyst Reni Benjamin maintains Zymeworks (NASDAQ:ZYME) with a Market Outperform and raises the price target from $32 to $39.

Read at benzinga.com